Market News
Stay updated with the latest market trends, earnings, and economic indicators.

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.

Here is the one sector bucking the trend in a weak market; Check out top gainers
Five among the top 10 gainers on the Nifty 500 index are Pharma stocks. They include Pfizer (Up 4.6%), Anthem Biosciences (Up 2.5%), Syngene (Up 2%), Aster DM Healthcare (Up 2%) and Wockhardt (Up 2%).

Himalaya Wealth launches ₹500 crore SME fund to back manufacturing, deeptech firms
The Category I AIF will target profitable growth-stage SMEs in sectors including aerospace, defence, industrial automation and healthcare, amid rising investor interest in manufacturing-led businesses.
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.

Nippon India Mutual Fund raises stake in this healthcare stock. Do you own? - Mint
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own?Mint
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.

Holding 10 or more mutual funds? You may be over-diversified — here’s the ideal number
While there is no magical number, most wealth advisors and financial planners that Mint talked to recommended that 4-6 funds spread across asset classes and stock categories can take care of the majority of the needs of an investor.
Nippon India Mutual Fund Increases Stake in Syngene International to 7.12% - scanx.trade
Nippon India Mutual Fund Increases Stake in Syngene International to 7.12%scanx.trade
MF Favourites take a hit: 14 smallcap stocks slide up to 50% in 3 months
Despite rising mutual fund stakes, several smallcap stocks have plunged up to 47% in 2026, highlighting market uncertainty and raising questions on whether these beaten-down picks offer value or further downside.

Kotak Mahindra Mutual Fund acquires stake in this recently listed healthcare stock
Kotak Mahindra Mutual Fund (KMMF) has raised its stake in the North Indian hospital network Park Medi World Limited to more than 5%. The fund purchased 175,164 shares, bringing its total ownership to 5.0393%, which necessitates a regulatory announcement in accordance with SAST regulations.

PE Firm True North Sells 3.6% Stake In Anthem Biosciences For Rs 1,261 Crore
HDFC Mutual Fund (MF) and SBI MF have collectively acquired 93,01,020 shares or 1.65% holding in Anthem Biosciences at an average price of Rs 621.10 apiece.